Patent application number | Description | Published |
20080200474 | NOVEL FLUNARIZINE SALT FORMS AND METHODS OF MAKING AND USING THE SAME - Disclosed herein are novel salts of flunarizine with improved properties. Also described herein are novel pharmaceutical compositions comprising such flunarizine salts, methods of making, and related methods of treatment. | 08-21-2008 |
20090030077 | Novel Fenofibrate Formulations and Related Methods of Treatment - The invention provides novel omega-3 oil liquid formulations of fenofibrate. These formulations can be substantially free of any food effect, effective in small volumes, and readily bioavailable. Notably, because the formulations of the invention contain an omega-3 oil as the major ingredient, they not only provide anithypercholesterolemic and antihypertriglyceridemic effects due to the fenofibrate active ingredient, they also provide recommended daily dosages of omega-3 oils (i.e., approximately 1 gram of omega-3 oil per day), or a portion thereof. | 01-29-2009 |
20090042979 | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment - The invention provides novel omega-3 oil formulations of one or more statins. These formulations are readily bioavailable. Notably, because the formulations of the invention contain an omega-3 oils as the major ingredient, they not only provide an antihypercholesterolemic effect due to the statin active ingredient, they also provide recommended daily dosages of omega-3 oils (i.e., approximately 1 gram of omega-3 oil per day), or a portion thereof. The invention also provides novel salts of one or more statins. | 02-12-2009 |
20090088443 | NOVEL CRYSTALLINE FORMS OF CONAZOLES AND METHODS OF MAKING AND USING THE SAME - The invention provides novel soluble conazole crystalline forms (e.g. itraconazole, posaconazole and saperconazole) that include salts, co-crystals and related solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, these conazole crystalline forms. Methods of using such compositions for the treatment or prevention of systemic and local fungal, yeast, and dermatophyte infections are also provided. | 04-02-2009 |
20090149533 | NOVEL FENOFIBRATE FORMULATIONS AND RELATED METHODS OF TREATMENT - The invention provides novel omega-3 ester-based oil solutions of fenofibrate. These solutions are substantially free of any food effect, effective in small volumes, and readily bioavailable. Notably, because the solutions of the invention contain an omega-3 ester-based oil as the major ingredient, they not only provide an antihyperlipidemic effect due to the fenofibrate active ingredient, they also provide recommended daily dosages of omega-3 oils (i.e., approximately 1 gram of omega-3 oil per day), or a portion thereof. | 06-11-2009 |
20100112051 | TIANEPTINE SULFATE SALT FORMS AND METHODS OF MAKING AND USING THE SAME - Disclosed herein is a novel sulfate salt of tianeptine with improved properties. Also described herein are novel pharmaceutical compositions comprising tianeptine sulfate salt, methods of making, and related methods of treatment. | 05-06-2010 |
20100279993 | Pharmaceutical Propylene Glycol Solvate Compositions - The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs. | 11-04-2010 |
Patent application number | Description | Published |
20110003828 | PRODRUGS OF NH-ACIDIC COMPOUNDS - The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment. | 01-06-2011 |
20110015156 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS - Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed. | 01-20-2011 |
20110166128 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders - The present invention provides prodrug compounds of diaryldiazepine drug compounds. | 07-07-2011 |
20110178068 | Quaternary Ammonium Salt Prodrugs - The invention provides a method of sustained delivery of a tertiary amine-containing parent drug comprising administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile quaternary ammonium salts of tertiary amine-containing parent drugs (or tertiary imine-containing parent drugs) that are derivatized through aldehyde-linked prodrug moieties that reduce the solubility of the prodrug compound at a reference pH as compared to the parent drug. The physical, chemical and solubility properties of these derivatives can be further modulated by the choice of counterion X | 07-21-2011 |
20110275803 | PROCESS FOR SYNTHESIZING OXIDIZED LACTAM COMPOUNDS - The invention provides a method for the synthesis of dehydrogenated lactam drugs of Formula I: | 11-10-2011 |
20110319422 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES - The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment. | 12-29-2011 |
20120015993 | Novel Pharmaceutical Forms, and Methods of Making and Using the Same - Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided. | 01-19-2012 |
20120028998 | CO-CRYSTAL OF ETRAVIRINE AND NICOTINAMIDE - Etravirine (TMC125) nicotinamide co-crystal, its preparation, and use in the treatment of HIV infection. | 02-02-2012 |
20120029205 | Hydrated Sodium Salt Form of Celecoxib - Hydrated celecoxib sodium salt forms and processes to prepare hydrated celecoxib sodium salt forms are disclosed. The celecoxib sodium salt forms are particularly useful and suitable for pharmaceutical applications. | 02-02-2012 |
20120238552 | PHARMACEUTICAL COMPOSITIONS COMPRISING SORBITAN ESTERS - The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs. | 09-20-2012 |
20130289280 | NOVEL PHARMACEUTICAL FORMS, AND METHODS OF MAKING AND USING THE SAME - Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided. | 10-31-2013 |
20140051852 | Process for Synthesizing Oxidized Lactam Compounds - The invention provides a method for the synthesis of dehydrogenated lactam drugs of Formula I: | 02-20-2014 |
20140088115 | PHARMACEUTICAL COMPOSITIONS HAVING IMPROVED STORAGE STABILITY - The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent | 03-27-2014 |
20140094472 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES - The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment. | 04-03-2014 |
20140221653 | Prodrugs of NH-Acidic Compounds - The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment. | 08-07-2014 |
20140350254 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders - Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed. | 11-27-2014 |